Velivet is the brand name for levetiracetam, a second‑generation antiepileptic drug (AED) widely used to control various seizure types. Below is a quick‑reference guide – handy if you’re a patient, caregiver or healthcare professional.
---
1. What is Velivet?
| Item | Details |
|------|---------|
| Generic | Levetiracetam |
| Brand | Velivet (Australia & New Zealand; other countries use the generic name) |
| Class | Non‑competitive, voltage‑gated sodium channel modulator; also acts on synaptic vesicle protein‑2A (SV2A) |
| Form | Oral tablet (15 mg, 75 mg, 300 mg, 750 mg) and oral suspension (25 mg/mL) |
| Bioavailability | ~100 % (well absorbed) |
| Half‑life | 4–7 h (dose‑dependent; ~7 h at steady state) |
| Renal excretion | 60–80 % unchanged; dose adjustment needed for renal impairment |
---
2. Indications
| Indication | Typical Use |
|------------|-------------|
| Focal (partial) seizures | With or without secondary generalization |
| Generalized tonic‑clonic seizures | Often as part of a polytherapy regimen |
| Myoclonic seizures (especially in juvenile myoclonic epilepsy) | Usually combined with another AED |
| Status epilepticus | Intravenous (IV) formulation – not part of this brand, but the same molecule |
Not approved for:
- Seizures secondary to brain tumor or trauma (unless part of broader management)
- Non‑epileptic events (e.g., psychogenic nonepileptic seizures)
---
3. How to Take Velivet
| Age Group | Starting Dose | Titration | Maintenance Dose |
|-----------|----------------|-----------|------------------|
| Adults (≥ 18 y) | 500 mg BID | +500 mg BID every 2–4 weeks | 1 g–4 g/day (split BID) |
| Children 2–11 y | 10 mg/kg BID (max 500 mg) | +10 mg/kg BID every 2–4 weeks | 10–25 mg/kg/day (max 3 g) |
| Children < 2 y | 5 mg/kg BID | +5 mg/kg BID every 2–4 weeks | 5–10 mg/kg/day |
| Pregnancy Category | N/A (use only if benefit outweighs risk) | — | — |
- Take with food if stomach upset occurs.
- Avoid abrupt discontinuation – taper over at least 4–6 weeks to reduce withdrawal seizure risk.
---
4. Common Adverse Effects
| Symptom | Frequency |
|---------|-----------|
| Drowsiness / fatigue | 10–20 % |
| Headache | 5–10 % |
| Irritability / mood change | 4–8 % |
| Dizziness | 5 % |
| Nausea, vomiting | < 5 % |
| Behavioral changes (agitation, aggression, depression) | < 5 % |
| Somnolence or sleep disturbances | < 5 % |
Rare but serious:
- Suicidal ideation/behavior
- Severe hypersensitivity reactions (rash, anaphylaxis)
- Renal impairment worsening (especially in pre‑existing CKD)
---
5. Contraindications
- Allergy to levetiracetam or any excipients
- Severe renal impairment (eGFR < 20 mL/min) – requires dose adjustment or alternative AED
- History of suicidal thoughts or significant psychiatric instability
---
6. Important Warnings & Precautions
1. Suicidal Thoughts / Behavior
– Monitor patients for mood changes, especially within the first 3 months of therapy or when doses are increased.
– Encourage patients/caregivers to report any new or worsening depression, anxiety, or suicidal ideation.
2. Renal Function
– Renal excretion is major. Dose must be adjusted in CKD: e.g., reduce maintenance dose by 50 % when eGFR 30–59 mL/min, by 75 % when eGFR < 30 mL/min.
3. Pregnancy & Lactation
– Limited human data; potential risk of fetal malformations (congenital heart defects, cleft palate).
– Breastfeeding: drug is excreted in milk; consider stopping if possible.
4. Drug Interactions
- CYP3A4 inhibitors/inducers (e.g., ketoconazole, carbamazepine, phenytoin) have minimal impact.
- Other AEDs (e.g., valproic acid, phenytoin) may increase levels of each other; monitor for toxicity.
- Antihistamines (diphenhydramine) may increase drowsiness.
5. Mental Health
– Report any mood or behavioral changes to prescriber.
– In patients with pre‑existing psychiatric conditions, consider baseline assessment.
6. Use in Elderly
– Older adults may experience increased sedation and falls; start low and titrate slowly.
---
7. Monitoring
| Parameter | Frequency | Why? |
|-----------|-----------|------|
| Seizure frequency & severity | Every visit (≥ 3 month intervals) | Assess efficacy |
| Renal function (serum creatinine, eGFR) | Every 3–6 months | Dose adjustment |
| Weight & growth (children) | Every visit | Detect growth delays or weight loss |
| Mood & behavior | Every visit | Early detection of suicidality |
| Blood counts | Rarely necessary unless combination therapy includes myelosuppressants |
---
8. Storage & Handling
- Keep in a dry, well‑ventilated place (21–25 °C / 70–75 % RH).
- Do not freeze.
- Keep out of reach of children.
- Do not exceed the prescribed dose; do not use if tablets are broken, crushed, or altered.
---
9. Key Take‑Away for Patients & Caregivers
- Take exactly as prescribed. Skipping doses or stopping abruptly can lead to rebound seizures.
- Report any new mood swings, depression, or thoughts of self‑harm immediately.
- Notify your clinician of any kidney problems or if you’re on other medications that may interact.
- Pregnancy? Discuss risks vs. benefits with your prescriber before starting or continuing therapy.
- Side‑effects such as drowsiness or headache usually improve with time or dose adjustment.
---
10. Quick Reference – Dosage Table
| Age / Weight | Starting Dose | Titration | Max Daily Dose |
|--------------|---------------|-----------|----------------|
| Adults | 500 mg BID | +500 mg BID q 2–4 wks | 4 g/day |
| 2–11 y | 10 mg/kg BID | +10 mg/kg BID q 2–4 wks | 25 mg/kg/day (≤ 3 g) |
| < 2 y | 5 mg/kg BID | +5 mg/kg BID q 2–4 wks | 10 mg/kg/day |
All doses should be split BID unless otherwise directed.
---
Bottom Line
Velivet (levetiracetam) is a well‑tolerated AED with a broad spectrum of seizure‑controlling activity. Its predictable pharmacokinetics make it a convenient option, especially for patients who need rapid seizure suppression or those with renal impairment (with dose adjustment). As with all AEDs, close monitoring for mood changes, renal function, and drug interactions is essential for safe and effective use. If you have any specific questions or concerns, discuss them with your prescriber or pharmacist.